Limaca Medical

About

Funding history · 2 rounds · $1.3M total

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is Limaca Medical's primary product?

Limaca Medical is developing KORA, an electro-mechanically driven endoscopic ultrasound-guided biopsy product designed for improved diagnosis of gastrointestinal system tumors.

When did Limaca Medical receive FDA Breakthrough Device designation for its Precision-GI product?

In May 2022, Limaca Medical's Precision-GI received Breakthrough Device designation from the FDA.

Which company is Limaca Medical affiliated with as an incubator company?

Limaca Medical is a company incubated by The Trendlines Group.

When did Limaca Medical announce its partnership in Japan?

In May 2022, Limaca Medical and HekaBio announced a partnership for the Japanese market.

What was the total amount raised by Limaca Medical in its Seed round?

In November 2020, Limaca Medical raised $1.25 million in a Seed funding round, with investors including The Trendlines Group and Carl Rickenbaugh. For full financing history, please refer to startupim.

When did Limaca Medical initiate its first-in-human study for its biopsy device?

In May 2019, Limaca Medical initiated its first-in-human study of its biopsy device for improved tumor diagnosis.

What is the current employee count for Limaca Medical?

Limaca Medical currently has 9 employees.

When did Limaca Medical launch its Precision-GI device in the US market?

In February 2025, Limaca Medical launched its Precision-GI™ endoscopic automated motorized EUS biopsy device in the US market.

What significant payment status did Limaca Medical's Precision-GI receive in November 2024?

In November 2024, Limaca Medical's Precision-GI™ was granted CMS Transitional Pass-Through (TPT) Payment.

Sectors & technology

Highlights

Tags